ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy
Seandean L. Harwood(Aarhus University), Luis Álvarez‐Vallina(Spanish National Cancer Research Centre)
Cited by 81
Related Papers
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
|Nature Communications|2018|143